Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade HuCC49 (DHK10004)

Host species:Humanized
Isotype:IgG1-nd
Applications:Research Grade Biosimilar
Expression system:XtenCHO
Overview

Catalog No.

DHK10004

Host species

Humanized

Species reactivity

Human

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Concentration

1 mg/ml

Purity

>95% by SDS-PAGE.

Clonality

Monoclonal

Isotype

IgG1-nd

Applications

Research Grade Biosimilar

Target

TAG-72

Purification

Protein A or G purified from cell culture supernatant.

Endotoxin level

Please contact with the lab for this information.

Expression system

XtenCHO

Accession

TAG-72

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Alternative Names

H22, MDX-33, H52, Huh52, HCC49, HuCC49, CAS: 823788-82-5

Note

For research use only. Not suitable for clinical or therapeutic use.

Data Image
  • SDS-PAGE
    SDS PAGE for HuCC49
References

TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using 225 Ac-Labeled DOTAylated-huCC49 Antibody, PMID: 32620701

Humanized Fluorescent Tumor-associated Glycoprotein-72 Antibody Selectively Labels Colon-cancer Liver Metastases in Orthotopic Mouse Models, PMID: 32871754

Humanized Anti-Tumor-Associated Glycoprotein-72 for Submillimeter Near-Infrared Detection of Colon Cancer in Metastatic Mouse Models, PMID: 32217350

A novel monoclonal antibody design for radioimmunotherapy, PMID: 14629823

A CDR-grafted (humanized) domain-deleted antitumor antibody, PMID: 10851481

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49, PMID: 8575795

Novel antibody hinge regions for efficient production of CH2 domain-deleted antibodies, PMID: 16221669

Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region, PMID: 16248766

Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues, PMID: 14522015

Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts, PMID: 12804050

111 In-(1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaaetic acid)-anti–TAG-72 humanized C H 2 domain-deleted antibody, PMID: 20641320

Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody, PMID: 10541352

Targeting strategies for cancer radiotherapy, PMID: 10541342

Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts, PMID: 10541333

Radioiodinated anti-TAG-72 humanized C H 2 domain-deleted antibody, PMID: 20641585

Synthesizing and binding dual-mode poly (lactic-co-glycolic acid) (PLGA) nanobubbles for cancer targeting and imaging, PMID: 20006382

Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49, PMID: 11255077

In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants, PMID: 14654532

Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies, PMID: 12215388

Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody, PMID: 16407221

Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute, PMID: 14513687

CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity, PMID: 10698310

Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes, PMID: 18309354

Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA), PMID: 10632041

Datasheet

Document Download

Research Grade HuCC49.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade HuCC49 [DHK10004]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only